Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
cervical cancer
field experience
oncoproteins E6/E7
women‐living with HIV
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
11 Apr 2024
11 Apr 2024
Historique:
revised:
19
02
2024
received:
06
11
2023
accepted:
07
03
2024
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
11
4
2024
Statut:
aheadofprint
Résumé
Overexpression of HPV-oncoproteins E6 and E7 is necessary for HPV-driven cervical carcinogenesis. Hence, these oncoproteins are promising disease-specific biomarkers. We assessed the technical and operational characteristics of the 8-HPV-type OncoE6/E7 Cervical Test in different laboratories using cervical samples from HPV-positive women living with (WLWH) and without HIV. The 8-HPV-type OncoE6/E7 Test (for short: "OncoE6/E7 test") was performed in 2833 HIV-negative women and 241 WLWH attending multicentric studies in Latin America (ESTAMPA study), and in Africa (CESTA study). Oncoprotein positivity were evaluated at each testing site, according to HIV status as well as type-specific agreement with HPV-DNA results. A feedback questionnaire was given to the operators performing the oncoprotein test to evaluate their impression and acceptability regarding the test. The OncoE6/E7 test revealed a high positivity rate heterogeneity across all testing sites (I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : UH2/3 CA202730
Pays : United States
Informations de copyright
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191‐e203.
Looker KJ, Rönn MM, Brock PM, et al. Evidence of synergistic relationships between HIV and human papillomavirus (HPV): systematic reviews and meta‐analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc. 2018;21(6):e25110.
Organization WH. Global strategy to accelerate the elimination of cervical cancer as a public health problem Secondary Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020 https://apps.who.int/iris/bitstream/handle/10665/336583/9789240014107-eng.pdf
World Health Organization. New recommendations for screening and treatment to prevent cervical cancer Secondary New recommendations for screening and treatment to prevent cervical cancer 2021. 2022 https://www.who.int/news/item/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer
Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine. 2006;24(Suppl 3):S3/63‐S3/70.
Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low‐ and middle‐income developing countries. Bull World Health Organ. 2001;79(10):954‐962.
Arianis Tatiana Ramirez JV, Baena A, Rojas FD, Ramirez K, Alvarez R, et al. Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study. The lancet regional. Health. 2023;26:1‐11.
Baena A, Mesher D, Salgado Y, et al. Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen‐positive women: results from the ESTAMPA study. Int J Cancer. 2023;152(8):1581‐1592.
Kelly H, Jaafar I, Chung M, et al. Diagnostic accuracy of cervical cancer screening strategies for high‐grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: a systematic review and meta‐analysis. EClinicalMedicine. 2022;53:101645.
Bradford L, Goodman A. Cervical cancer screening and prevention in low‐resource settings. Clin Obstet Gynecol. 2013;56(1):76‐87.
Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:2.
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31‐46.
Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40(1):1‐13.
Narisawa‐Saito M, Kiyono T. Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505‐1511.
Wardak S. Human papillomavirus (HPV) and cervical cancer. Med Dosw Mikrobiol. 2016;68(1):73‐84.
McBride AA, Warburton A. The role of integration in oncogenic progression of HPV‐associated cancers. PLoS Pathog. 2017;13(4):e1006211.
Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15(3):266‐282.
Araldi RP, Sant'Ana TA, Módolo DG, et al. The human papillomavirus (HPV)‐related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537‐1556.
Boccardo E, Baldi CVM, Carvalho AF, et al. Expression of human papillomavirus type 16 E7 oncoprotein alters keratinocytes expression profile in response to tumor necrosis factor‐alpha. Carcinogenesis. 2010;31(3):521‐531.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550‐560.
Yeo‐Teh NSL, Ito Y, Jha S. High‐risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci. 2018;19(6):1‐27.
Cardeal LB, Boccardo E, Termini L, et al. HPV16 oncoproteins induce MMPs/RECK‐TIMP‐2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One. 2012;7(3):e33585.
Boccardo E, Lepique AP, Villa LL. The role of inflammation in HPV carcinogenesis. Carcinogenesis. 2010;31(11):1905‐1912.
Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high‐risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009;19(2):97‐113.
Zhang Q, Dong L, Hu SY, et al. Risk stratification and long‐term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer. 2017;141(6):1110‐1119.
Yu LL, Kang LN, Zhao FH, et al. Elevated expression of human Papillomavirus‐16/18 E6 oncoprotein associates with persistence of viral infection: a 3‐year prospective study in China. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1167‐1174.
Yu L, Jiang M, Qu P, et al. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage. Int J Cancer. 2018;143(4):813‐822.
Ferrera A, Valladares W, Cabrera Y, et al. Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer. Int J Cancer. 2019;145(8):2042‐2050.
Rezhake R, Hu SY, Zhao S, et al. Eight‐type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV‐positive women. Int J Cancer. 2019;144(1):34‐42.
Valdez M, Jeronimo J, Bansil P, et al. Effectiveness of novel, lower cost molecular human papillomavirus‐based tests for cervical cancer screening in rural China. Int J Cancer. 2016;138(6):1453‐1461.
Ndizeye Z, Menon S, Van Geertruyden J‐P, et al. Performance of OncoE6 (TM) cervical test in detecting cervical precancer lesions in HIV‐positive women attending an HIV clinic in Bujumbura, Burundi: a cross‐sectional study. BMJ Open. 2019;9(9):e029088.
Almonte M, Murillo R, Sánchez GI, et al. Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. BMJ Open. 2020;10(5):e035796.
Trial.gov C. The study for the "cervical cancer screening and treatment algorithms study using HPV testing in Africa" (CESTA). Secondary the study for the "cervical cancer screening and treatment algorithms study using HPV testing in Africa" (CESTA). https://classic.clinicaltrials.gov/ct2/show/NCT04794660
Correa RM, Baena A, Valls J, et al. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS One. 2022;17(7):e0272205.
Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, et al. Prevalence and distribution of HPV genotypes among HIV‐infected women in Zambia. Br J Cancer. 2007;96(9):1480‐1483.
Luchters SM, Vanden Broeck D, Chersich MF, et al. Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers. BMC Infect Dis. 2010;10:18.
Clifford GM, de Vuyst H, Tenet V, Plummer M, Tully S, Franceschi S. Effect of HIV infection on human papillomavirus types causing invasive cervical cancer in Africa. J Acquir Immune Defic Syndr. 2016;73(3):332‐339.
Mbuya W, Held K, McHaro RD, et al. Depletion of human papilloma virus E6‐ and E7‐oncoprotein‐specific T‐cell responses in women living with HIV. Front Immunol. 2021;12:742861.
Park S, Auyeung A, Lee DL, Lambert PF, Carchman EH, Sherer NM. HIV‐1 protease inhibitors slow HPV16‐driven cell proliferation through targeted depletion of viral E6 and E7 oncoproteins. Cancers (Basel). 2021;13(5):1‐16.
Makgoo L, Mosebi S, Mbita Z. Molecular mechanisms of HIV protease inhibitors against HPV‐associated cervical cancer: restoration of TP53 tumour suppressor activities. Front Mol Biosci. 2022;9:875208.
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta‐analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789‐1799.
Chachage M, Parikh AP, Mahenge A, et al. High‐risk human papillomavirus genotype distribution among women living with and at risk for HIV in Africa. Aids. 2023;37(4):625‐635.
Chen Z, Schiffman M, Herrero R, et al. Classification and evolution of human papillomavirus genome variants: Alpha‐5 (HPV26, 51, 69, 82), Alpha‐6 (HPV30, 53, 56, 66), Alpha‐11 (HPV34, 73), Alpha‐13 (HPV54) and Alpha‐3 (HPV61). Virology. 2018;516:86‐101.
Rezhake R, Chen F, Hu S‐Y, et al. Triage options to manage high‐risk human papillomavirus‐positive women: a population‐based cross‐sectional study from rural China. Int J Cancer. 2020;147(8):2053‐2064.